Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 13/20 | 0.46 |
| ▸ | HRH1 | P35367 | 13/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243245 | 0.90 | HRH2 (0.44) | HRH2HRH1HRH3KCNA5MMP2 | |
| SCHEMBL7245961 | 0.87 | HRH2 (0.45) | HRH2HRH1HRH3KCNA5MMP2 | |
| SCHEMBL7252155 | 0.86 | KCNA5 (0.48) | HRH2HRH1HRH3KCNA5 | |
| SCHEMBL7245870 | 0.86 | HRH2 (0.45) | HRH2HRH1HRH3KCNA5 | |
| SCHEMBL7623346 | 0.85 | KCNH2 (0.49) | — | |
| SCHEMBL7252363 | 0.85 | HRH2 (0.48) | HRH2HRH1HRH3KCNA5 | |
| SCHEMBL7246185 | 0.85 | KCNA5 (0.59) | HRH2HRH1HRH3KCNA5MMP2 | |
| SCHEMBL7242815 | 0.82 | CCR3 (0.41) | HRH2HRH1HRH3 | |
| SCHEMBL7245432 | 0.82 | HRH2 (0.43) | HRH2HRH1HRH3KCNA5 | |
| SCHEMBL7243497 | 0.82 | HRH2 (0.43) | HRH2HRH1HRH3KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559162-B2 | Electrophysiological activity | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | KCNH1, KCNH2, KCNH3 | HRH2 321/4885HRH1 367/4885HRH3 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.